166 related articles for article (PubMed ID: 12602762)
1. Current status of selective estrogen receptor modulators (SERMs).
Conzen SD
Cancer J; 2003; 9(1):4-14. PubMed ID: 12602762
[No Abstract] [Full Text] [Related]
2. Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.
Pickar JH; Komm BS
Post Reprod Health; 2015 Sep; 21(3):112-21. PubMed ID: 26289836
[TBL] [Abstract][Full Text] [Related]
3. Re: Playing the old piano: another tune for endocrine therapy.
Koeberle D; Perey L; Thuerlimann B;
J Natl Cancer Inst; 2004 Apr; 96(7):555-6; author reply 556-7. PubMed ID: 15069120
[No Abstract] [Full Text] [Related]
4. Pure antiestrogens and breast cancer.
Elkak AE; Mokbel K
Curr Med Res Opin; 2001; 17(4):282-9. PubMed ID: 11922402
[TBL] [Abstract][Full Text] [Related]
5. Selective estrogen receptor modulators as a new therapeutic drug group: concept to reality in a decade.
Gajdos C; Jordan VC
Clin Breast Cancer; 2002 Jan; 2(4):272-81. PubMed ID: 11899358
[TBL] [Abstract][Full Text] [Related]
6. Approaches targeted to estrogen receptors for treatment of tamoxifen-resistant breast cancer: a brief overview.
Terakawa N
Oncology; 2000; 59 Suppl 1():3-4. PubMed ID: 11096349
[No Abstract] [Full Text] [Related]
7. Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells.
Frasor J; Stossi F; Danes JM; Komm B; Lyttle CR; Katzenellenbogen BS
Cancer Res; 2004 Feb; 64(4):1522-33. PubMed ID: 14973112
[TBL] [Abstract][Full Text] [Related]
8. EM-652 (SCH57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium.
Labrie F; Labrie C; Bélanger A; Simard J; Giguère V; Tremblay A; Tremblay G
J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):213-25. PubMed ID: 11850228
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer chemoprevention: a review of selective estrogen receptor modulators.
Johansen AM
Clin J Oncol Nurs; 2005 Jun; 9(3):317-20. PubMed ID: 15973842
[TBL] [Abstract][Full Text] [Related]
10. Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer.
Hoffmann J; Bohlmann R; Heinrich N; Hofmeister H; Kroll J; Künzer H; Lichtner RB; Nishino Y; Parczyk K; Sauer G; Gieschen H; Ulbrich HF; Schneider MR
J Natl Cancer Inst; 2004 Feb; 96(3):210-8. PubMed ID: 14759988
[TBL] [Abstract][Full Text] [Related]
11. Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH-toremifene, droloxifene, and raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells.
Simard J; Sanchez R; Poirier D; Gauthier S; Singh SM; Merand Y; Belanger A; Labrie C; Labrie F
Cancer Res; 1997 Aug; 57(16):3494-7. PubMed ID: 9270018
[TBL] [Abstract][Full Text] [Related]
12. A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats.
Greenberger LM; Annable T; Collins KI; Komm BS; Lyttle CR; Miller CP; Satyaswaroop PG; Zhang Y; Frost P
Clin Cancer Res; 2001 Oct; 7(10):3166-77. PubMed ID: 11595711
[TBL] [Abstract][Full Text] [Related]
13. Progress in the prevention of breast cancer: concept to reality.
Jordan VC
J Steroid Biochem Mol Biol; 2000 Nov; 74(5):269-77. PubMed ID: 11162935
[TBL] [Abstract][Full Text] [Related]
14. Modern antioestrogens and the coming revolution in women's health care.
Evans A; Vollenhoven B; Healy D
Aust N Z J Obstet Gynaecol; 1999 Aug; 39(3):334-40. PubMed ID: 10554946
[TBL] [Abstract][Full Text] [Related]
15. Tamoxifen and ICI 182,780 negatively influenced cardiac cell growth via an estrogen receptor-independent mechanism.
Mercier I; Mader S; Calderone A
Cardiovasc Res; 2003 Oct; 59(4):883-92. PubMed ID: 14553828
[TBL] [Abstract][Full Text] [Related]
16. Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention.
Park WC; Jordan VC
Trends Mol Med; 2002 Feb; 8(2):82-8. PubMed ID: 11815274
[TBL] [Abstract][Full Text] [Related]
17. Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective.
Robertson JF
Cancer Treat Rev; 2004 Dec; 30(8):695-706. PubMed ID: 15541579
[TBL] [Abstract][Full Text] [Related]
18. Effects of selective estrogen receptor modulators (SERMs) on coactivator nuclear receptor (NR) box binding to estrogen receptors.
Bramlett KS; Burris TP
Mol Genet Metab; 2002 Jul; 76(3):225-33. PubMed ID: 12126937
[TBL] [Abstract][Full Text] [Related]
19. Estrogen induces death of tamoxifen-resistant MCF-7 cells: contrasting effect of the estrogen receptor downregulator fulvestrant.
Planas-Silva MD; Waltz PK; Kilker RL
J Steroid Biochem Mol Biol; 2006 Mar; 98(4-5):193-8. PubMed ID: 16464573
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel oestrogen receptor target genes in human ZR75-1 breast cancer cells by expression profiling.
Soulez M; Parker MG
J Mol Endocrinol; 2001 Dec; 27(3):259-74. PubMed ID: 11719280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
